Tags

Type your tag names separated by a space and hit enter

Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
Semin Hematol. 1986 Apr; 23(2):132-43.SH

Abstract

The PVSG was organized in 1967 to establish effective diagnostic criteria for polycythemia vera, to study the natural history of the disease and to define the optimal treatment. Although polycythemia vera and the other myeloproliferative diseases are relatively uncommon, the PVSG was able to accumulate well over 1,000 patients with these various disorders and to study them according to a total of 15 different protocols. PVSG-01, a long-term randomized controlled study of phlebotomy alone compared with the myelosuppressive agents, 32P or chlorambucil supplemented by phlebotomy, continues to receive follow-up data on 93% of surviving patients 18 years after initiation of the study. During its lifetime, PVSG has developed a widely accepted and highly effective set of criteria for the specific diagnosis of polycythemia vera as well as useful criteria for the diagnosis of essential thrombocythemia. It has gathered an enormous volume of data on the natural history of the myeloproliferative diseases and in particular on the nature of the prevalent complications, such as thrombotic events and hematologic and nonhematologic malignancies. With respect to the final question, the optimal treatment for polycythemia vera, it is apparent that the expectation of a single optimal therapy that would apply to all patients at all ages and stages of the disease was naive. Nevertheless considerable progress has been made. Moreover, the group has defined more precisely than ever before the nature of the complications of the disease and the association of the risks of specific complications with specific forms of therapy. It thus has made it possible to pose the next series of therapeutic questions that must be addressed in this disorder with a greater degree of sophistication than was previously possible.

Authors

Berk PD
No affiliation info available
Goldberg JD
No affiliation info available
Donovan PB
No affiliation info available
Fruchtman SM
No affiliation info available
Berlin NI
No affiliation info available
Wasserman LR
No affiliation info available

MeSH

Acute DiseaseAge FactorsBloodlettingChlorambucilCombined Modality TherapyFalse Positive ReactionsFollow-Up StudiesGastrointestinal NeoplasmsGoutHematocritHumansHydroxyureaLeukemiaPhosphorus RadioisotopesPlatelet AggregationPlatelet CountPolycythemia VeraProspective StudiesPruritusSkin NeoplasmsThrombosis

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

3704665

Clinical Trial Links

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

Citation

Berk, P D., et al. "Therapeutic Recommendations in Polycythemia Vera Based On Polycythemia Vera Study Group Protocols." Seminars in Hematology, vol. 23, no. 2, 1986, pp. 132-43.
Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-43.
Berk, P. D., Goldberg, J. D., Donovan, P. B., Fruchtman, S. M., Berlin, N. I., & Wasserman, L. R. (1986). Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Seminars in Hematology, 23(2), 132-43.
Berk PD, et al. Therapeutic Recommendations in Polycythemia Vera Based On Polycythemia Vera Study Group Protocols. Semin Hematol. 1986;23(2):132-43. PubMed PMID: 3704665.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. AU - Berk,P D, AU - Goldberg,J D, AU - Donovan,P B, AU - Fruchtman,S M, AU - Berlin,N I, AU - Wasserman,L R, PY - 1986/4/1/pubmed PY - 1986/4/1/medline PY - 1986/4/1/entrez SP - 132 EP - 43 JF - Seminars in hematology JO - Semin Hematol VL - 23 IS - 2 N2 - The PVSG was organized in 1967 to establish effective diagnostic criteria for polycythemia vera, to study the natural history of the disease and to define the optimal treatment. Although polycythemia vera and the other myeloproliferative diseases are relatively uncommon, the PVSG was able to accumulate well over 1,000 patients with these various disorders and to study them according to a total of 15 different protocols. PVSG-01, a long-term randomized controlled study of phlebotomy alone compared with the myelosuppressive agents, 32P or chlorambucil supplemented by phlebotomy, continues to receive follow-up data on 93% of surviving patients 18 years after initiation of the study. During its lifetime, PVSG has developed a widely accepted and highly effective set of criteria for the specific diagnosis of polycythemia vera as well as useful criteria for the diagnosis of essential thrombocythemia. It has gathered an enormous volume of data on the natural history of the myeloproliferative diseases and in particular on the nature of the prevalent complications, such as thrombotic events and hematologic and nonhematologic malignancies. With respect to the final question, the optimal treatment for polycythemia vera, it is apparent that the expectation of a single optimal therapy that would apply to all patients at all ages and stages of the disease was naive. Nevertheless considerable progress has been made. Moreover, the group has defined more precisely than ever before the nature of the complications of the disease and the association of the risks of specific complications with specific forms of therapy. It thus has made it possible to pose the next series of therapeutic questions that must be addressed in this disorder with a greater degree of sophistication than was previously possible. SN - 0037-1963 UR - https://www.unboundmedicine.com/medline/citation/3704665/Therapeutic_recommendations_in_polycythemia_vera_based_on_Polycythemia_Vera_Study_Group_protocols_ DB - PRIME DP - Unbound Medicine ER -